Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective

Metabolic dysfunction-associated steatohepatitis (MASH) is emerging as a leading cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality worldwide. Among the most advanced pharmacologic candidates are resmetirom, a highly liver-selective thyroid hormone receptor-β (THR-β) agonist,...

Descripció completa

Dades bibliogràfiques

Autor principal:	Ralf Weiskirchen
Format:	Artigo
Idioma:	Inglês
Publicat:	Open Exploration 2025-10-01
Col·lecció:	Exploration of Drug Science
Matèries:	masld therapy drugs thyroid hormone receptor-β agonist glp-1 receptor agonist
Accés en línia:	https://www.explorationpub.com/uploads/Article/A1008132/1008132.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!